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Summary
BRAF
V600E/K is a frequent mutationally active tumor-speciﬁc kinase in melanomas that is currently targeted
for therapy by the speciﬁc inhibitor PLX4032. Our studies with melanoma tumor cells that are BRAF
V600E/K
and BRAF
WT showed that, paradoxically, while PLX4032 inhibited ERK1/2 in the highly sensitive BRAF
V600E/K,
it activated the pathway in the resistant BRAF
WT cells, via RAF1 activation, regardless of the status of muta-
tions in NRAS or PTEN. The persistently active ERK1/2 triggered downstream effectors in BRAF
WT melanoma
cells and induced changes in the expression of a wide-spectrum of genes associated with cell cycle control.
Furthermore, PLX4032 increased the rate of proliferation of growth factor-dependent NRAS Q61L mutant
primary melanoma cells, reduced cell adherence and increased mobility of cells from advanced lesions. The
results suggest that the drug can confer an advantage to BRAF
WT primary and metastatic tumor cells in vivo
and provide markers for monitoring clinical responses.
Introduction
Tumor-speciﬁc activated kinases that confer uncon-
trolled cell proliferation to cancer cells and promote
metastasis have been attractive targets for therapy,
because cancer cells are often dependent on this class
of molecule, a condition termed ‘oncogene addiction’,
while normal cells are not (Sharma and Settleman,
2007; Weinstein and Joe, 2008). Consistent with
this paradigm are the clinical successes with the
Signiﬁcance
The identiﬁcation of druggable kinases in cancers is currently a promising approach for the development
of patient-tailored therapy. However, tumors harbor various mutations in proliferation⁄survival pathways
that can diminish drug efﬁcacy. We report here studies on the effects of PLX4032 on short-term cultures
of human melanoma cells that have been characterized for mutations in known genes. PLX4032 is a
BRAF
V600K kinase inhibitor that has demonstrated encouraging responses in current Phase I⁄II clinical tri-
als. We explored the mechanism by which non-responsive BRAF
WT melanoma cells escape inhibition and
show that these cells are stimulated by the drug in ways that can confer growth advantage in vitro. Our
results suggest that only patients with mutant BRAF-V600K⁄E should be selected for treatment and that
patients should be monitored for any secondary tumors that may not carry the BRAF mutation, or for
recurrences of tumor cells that have lost the mutant BRAF allele.
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chronic myelogenous leukemia and gastrointestinal
stromal tumors, cancers dependent on the ABL kinase
and the receptor kinase c-KIT, respectively (Sharma and
Settleman, 2007; Weinstein and Joe, 2008). Likewise,
melanoma patients with activating mutations in c-Kit are
also being treated with Imatinib (acral and mucosal mel-
anomas) (Curtin et al., 2006; Dhomen and Marais, 2009;
Hodi et al., 2008; Jiang et al., 2008), and those with
activated BRAF, present in about 60% of cases (Forbes
et al., 2008; Smalley et al., 2009), are currently selected
for enrollment in phase I⁄II clinical trials with PLX4032,
an inhibitor of activated BRAF
V600E that has generated
promising outcomes (Flaherty et al., 2009 and http://
www.news-medical.net/news/20090930/Plexxikon-com-
mences-patient-dosage-in-PLX4032-trials-for-metastatic-
melanoma.aspx).
Here, we assessed the effects of PLX4032 on freshly
isolated cultured melanoma cells harboring different
mutations and explored the mechanism by which non-
responsive BRAF
WT melanoma cells escape drug inhibi-
tion. We demonstrate that, paradoxically, whereas
PLX4032 inhibited extracellular signal-regulated kinase
(ERK) in BRAF
V600E ⁄ K-mutants, it induced the pathway
in BRAF
WT melanoma cells via activation of RAF1.
PLX4032 promoted the proliferation of growth factor-
dependent, NRAS mutant, primary melanoma cells,
reduced cell adhesion and increased cell motility of
highly proliferating, mitogen- independent advanced mel-
anoma cells.
Results
Growth responses of melanoma cells to PLX4032
The effect of PLX4032 was tested on melanoma cells
isolated from primary and metastatic lesions in which
BRAF, NRAS and PTEN mutations were characterized
(Table 1). Dose response analyses showed that all the
BRAF mutant melanoma cell strains were highly sensi-
tive to PLX4032 with IC50 in the nM range (60–450 nM),
whereas BRAF wild-type cells were resistant, with IC50
2.4 lM or above (Figure 1A), consistent with published
information (Tsai et al., 2008). Interestingly, three of
four heterozygous V600E⁄WT cell strains (501 mel,
YUKOLI and YUSIK) were slightly, but signiﬁcantly more
resistant compared with the other mutant cells
(Figure 1A, green solid lines). The differences were sta-
tistically signiﬁcant across a wide range of PLX4032
concentrations as shown by the two-sample Wilco-
xon rank sum test (Figure 1B). The outlier, YUMUT-
BRAF
V600E ⁄ WT melanoma cells, are also PTEN null and
further examination is needed to establish whether
mutations complementing the heterozygous V600E
mutation confer more sensitivity to the drug. Different
levels of BRAF or RAF1 (also known as c-RAF) proteins
(Figure S1) could not explain the differences in growth
responses to PLX4032. The results demonstrated that
drug response can be modulated by the BRAF genotype
but is not affected by mutations in NRAS or downregu-
lation of PTEN in BRAF
WT melanoma cells isolated from
advanced lesions.
A
B
Figure 1. Growth responses to PLX4032. (A) CellTiter-Glo  Luminescent Cell Viability Assay. Values are percent of control (DMSO) assessed
at the end of 72-h treatment with PLX4032 (1 lM). Each measurement is the average of triplicate or quadruplet wells. The legend on the right
provides the IC50 indicating melanoma cells that are BRAF homozygous or heterozygous for wild-type (W), V600K (K) or V600E (E) mutation.
Among the BRAF
WT cell strains, YUDOSO and YUFIC are heterozygous for the NRAS Q61K and Q61R mutation, respectively (dotted black
line), and YUDEDE cells are null for PTEN and carry homozygous NRAS Q61H mutation (dashed black line). Green and red dashed lines indicate
BRAF mutant cells null for PTEN. The horizontal dashed line marked IC50. STDV was about 5% of total count. (B) A two-sample Wilcoxon rank
sum test assessing differences in growth responses of wild-type and mutant melanoma cells at several concentrations of PLX4032. The
graphs, plotted as logarithm of the P-values (y-axis) over PLX4032 concentration show signiﬁcant differences over a broad range of PLX4032
concentrations in the response of cells carrying the heterozygous BRAF
V600E ⁄ WT alleles compared to BRAF
WT melanoma cells (red), and
BRAF
V600E ⁄ WT compared with other mutant cells, i.e. homozygous BRAF
V600E ⁄ E, BRAF
V600K ⁄ K or heterozygous BRAF
V600K ⁄ WT (black).
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The effects of PLX4032 on downstream RAF effectors
were examined to further understand the mechanism of
drug resistance. Unless otherwise stated, we used
1 lM of PLX4032, about 10· the IC50 of sensitive mela-
noma cells, and equal amounts of the solvent DMSO
(0.1%) as a control. Consistent with published data (Sala
et al., 2008; Tsai et al., 2008), PLX4032 abolished the
ERK1⁄2 activating phosphorylation in BRAF
V600E ⁄ K mela-
noma cells (Figure 2, pERK, YULAC, YURIF, YUMAC
and YUGEN8). However, unlike published reports,
PLX4032 induced ERK1⁄2 phosphorylation in BRAF
WT
melanoma cells (Figure 2, pERK, YUKIM, YUDOSO and
YUFIC). Increased ERK1⁄2 phosphorylation in these cells
was persistent and was independent from the status of
PTEN (compare YUDOSO with YUFIC), or the presence
of NRAS activating mutation (compare the NRAS wild-
type YUKIM with NRAS mutant YUDOSO and YUFIC
cells). In addition, mutationally active b-catenin did not
diminish the effect of PLX4032 on BRAF
V600K mutant
melanoma cells (Figure 2, YURIF). Examination of MEK,
the upstream activator of ERK, showed a similar pattern
of inactivation and activation in response to PLX4032
(Figure 2, pMEK), demonstrating that while the RAF-
MEK-ERK pathway was inhibited in BRAF mutants, it
was activated in BRAF
wt melanoma cells.
Changes in dephosphorylation and hyperphosphoryla-
tion of ERK1⁄2 in YULAC-BRAF
V600E and YUDOSO-
BRAF
WT melanoma cells, respectively, occurred within
5 min, and progressed with similar kinetics (Figure 2B,
pERK). The Western blots also showed that the levels
of total ERK1⁄2 protein in BRAF
WT cell lysates
decreased after treatment with PLX4032 (Figure 2A,
ERK, YUKIM, YUDOSO and YUFIC, compare 0 to 4 and
8 h drug treatment, and Figure 2B, YUDOSO), although
actin levels were the same (Figure 2A, B, actin).
Because activated ERK1⁄2 translocates to the nucleus
and might have remained RIPA insoluble, we examined
the particulate fractions after solubilization in SDS-sam-
ple buffer, heating and sonication. The results show
enrichment of phospho-ERK1⁄2 and total ERK1⁄2 in the
particulate compartment of YUDOSO-BRAF
WT after
treatment with PLX4032 (Figure 2C, compare lanes
marked Sup and Part).
The opposite effects of PLX4032 on ERK1⁄2 phos-
phorylation in YULAC-BRAF
V600E and YUDOSO-BRAF
WT
melanoma cells were concentration dependent. Both
cell types responded to the drug at 1 and 0.5 lM, but
not at 0.1 lM (Figure 2D), in good agreement with the
known IC50 of PLX4032 against puriﬁed BRAF
V600E
kinase (44 nmol⁄l) (Sala et al., 2008).
Other intracellular signaling pathways were not, or
slightly affected by PLX4032. We did not detect engage-
ment of the AKT pathway (Figure S2A, pS6K and pAKT).
There were only slight changes in the activated form of
p38MAPK in YULAC-BRAF
V600E and YUDOSO-BRAF
WT
in response to the drug (Figure S2B). Although the lev-
els of phospho JNK T183⁄Y185 were induced within
30 min of PLX4032 treatment (Figure S2C), there were
no changes in the activated status of several known
downstream JNK targets, such as p53, JUN and eIF4E
in YUDOSO-BRAF
WT melanoma cells, whereas only
phospho-eIF4E Ser209 levels were reduced in YULAC-
BRAF
V600E cells (Figure S2D), suggesting very little
functional consequences of JNK activation on BRAF
WT
melanoma cells. We therefore focused our studies on
the ERK pathway.
PLX4032 activates RAF1 in BRAF
WT melanoma cells
We ruled out ERK activation by MEKK1 (Lu et al., 2002)
because YUKIM melanoma cells in which ERK1⁄2 was
highly activated in response to PLX4032 (Figure 2A)
did not express the protein (data not shown). We also
ruled out MEKK3 (Craig et al., 2008), because this
A
B
D
C
Figure 2. Changes in ERK1⁄2 and MEK in response to PLX4032.
(A) Melanoma cell strains were treated with DMSO for 4 h (0), or
with PLX4032 (1 lM) for 4 and 8 h. The panels show Western
blots probed with antibodies to phosph-ERK1⁄2 Thr202⁄Tyr204
mAb (pERK), ERK1⁄2 (ERK), phospho-MEK1⁄2 (pMEK), MEK1⁄2
(MEK), and actin as a loading control. The mutation status of
BRAF, NRAS, PTEN and b-catenin (bCAT) are indicated at the top.
(B) Western blot analyses of ERK1⁄2 inactivation⁄activation after
short-term incubation with PLX4032 (1 lM). (C) pERK1⁄2 and
ERK1⁄2 in supernatant (Sup) and particulate (Part) fractions. (D)
Changes in pERK1⁄2 activation after treatments with increasing
concentration of PLX4032, or DMSO for 1 h.
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(Figure S4). Suppression of two dual-speciﬁcity phos-
phatases, MKP-1 and MKP5 was also an unlikely mech-
anism, because the two remained unchanged in
YUDOSO-BRAF
WT cells after treatment with PLX4032
(data not shown).
We therefore assessed BRAF and RAF1 enzymatic
activity. Immune-complexes kinase assays showed, as
expected, high BRAF activity in YULAC-BRAF
V600E and
YUMAC-BRAF
V600K cells that was suppressed after
treatment with PLX4032 for 30 min (Figure 3A, YULAC
and YUMAC). In BRAF
WT melanoma cells, BRAF was
either not detectable or was about 10- to 50-fold less
active than its mutant counterpart. In cases when activ-
ity was measurable, PLX4032 inhibited the wild-type
BRAF kinase as well (Figure 3A, YUFIC).
Similar studies with RAF1 showed non-detectable
activity in YULAC-BRAF
V600E and YUMAC-BRAF
V600K
cells (data not shown). In contrast, a wide range of
RAF1 kinase activity was observed in four independent
BRAF
WT melanoma cells (0.03–3.7 pmol ATP⁄min), that
in all cases was further increased after treatments with
PLX4032 (Figure 3B). Furthermore, ﬁvefold reduction in
RAF1 levels in YUFIC-BRAF
WT melanoma cells by siRNA
(Figure 3C, compare RAF1 bands with actin as the load-
ing control, and Figure 3D, RAF1⁄actin ratio) caused a
similar fold suppression in PLX4032 induced ERK activa-
tion compared with non-treated cells (Figure 3C, pERK
and ERK, and Figure 3D, pERK⁄ERK ratio), lending sup-
port to the conclusion that RAF1 is the main kinase that
caused ERK activation.
A
CD E
B
Figure 3. RAF kinase in response to PLX4032. (A, B, E) Immune-complex kinase activities expressed as picomoles [c-
32P]-ATP incorporated
into MBP. Each data point is an average of triplicate measurements ± STDV. The cells were treated with PLX4032 for 1 h (A), 4 h (B) and
16 h (E). The panels under each kinase assay shows Western blots of immunoprecipitated proteins eluted with SDS sample buffer and
probed with antibodies to the respective protein. Numbers under the protein bands in (B) and (E) indicate relative band density determined by
densitometric analysis. (C) Suppression of PLX4032 induced ERK activation in YUFIC-BRAF
WT melanoma after RAF1 depletion by siRNA.
YUFIC melanoma cells were transfected with Alexa Fluor or RAF1 siRNA and 2 days later were treated with PLX4032 or DMSO for 1 h. Cell
lysates were probed with the indicated antibodies. The numbers under each blot represent values of band density in pixels 1 · 10
3. (D)
Histograms showing band intensity ratios normalizing RAF1 to actin and pERK to total ERK as presented in (C).
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PLX4032 could activate RAF1. We ruled out triggering
an escape pathway, such as a receptor tyrosine kinase,
by two independent approaches. First, traditional
Western blotting with anti-RAF1 phospho-speciﬁc
antibodies failed to detect an increase in RAF1(S338)
or RAF1(S259) phosphorylation (Figure S3A, B). There
was a persistent increase only in phospho-RAF1
(Ser289⁄296⁄301), the ERK1⁄2 phosphorylation sites, in
BRAF
WT cells treated with the drug (Figure S3A, B).
However, the phosphorylation of these sites serves as
a feedback mechanism to attenuate ERK1⁄2 activity
(Baccarini, 2005) and therefore cannot explain RAF1
activation. Second, transiently expressed mutant RAF1
R89L, that does not bind Ras-GTP, a critical step in
receptor-mediated stimulation, was activated by
PLX4032 to the same extent as ectopically expressed
wild-type RAF1 (Figure 3E). We therefore concluded
that PLX4032 did not activate an upstream RAF1 kinase
escape pathway.
Another major mechanism for RAF1 activation is
homodimerization or heterodimerization with wild-type
or enzymatically impaired mutant BRAF (Garnett et al.,
2005; Heidorn et al., 2010; Rajakulendran et al., 2009;
Rushworth et al., 2006). However, we could not demon-
strate co-immunoprecipitation of endogenous BRAF
with RAF1, or transiently transfected MYC and FLAG
tagged RAF1 in PLX4032-treated melanoma cells under
conditions in which RAF1 was activated by the drug.
Differential activation of downstream ERK1 targets
We further explored the activation of downstream ERK
targets and changes in gene expression that may shed
more light on PLX4032 cellular responses and may pro-
vide markers to monitor therapy. Western blotting with
phospho-speciﬁc p90
RSK antibodies revealed marked
activation of this ERK1⁄2 effector in YUDOSO-BRAF
WT
melanoma cells, while it was inhibited in YULAC-
BRAF
V600E (Figure 4A, p90
RSK, T573, S380 and T359⁄
S36). The nuclear resident transcription factor CREB, a
A
C
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Figure 4. Inactivation⁄activation of downstream ERK targets in response to PLX4032. (A, B) Western blots showing changes in p90
RSK and
CREB activation states, respectively, employing phospho-speciﬁc antibodies. (C) Changes in c-FOS and JUNB gene transcripts in response to
PLX4032 as evaluated by Real Time RT-PCR. Data are averages of three replicates ± STDV. (D) Heatmap showing upregulation of gene
expression by at least 3-fold and above in YUDOSO-BRAF
WT melanoma cells in response to treatment with PLX4032 for 8 and 24 h
employing the NimbleGen whole genome expression arrays. Marked in red circles are IL8 and LIF. (E) ELISA assay conﬁrming an increase in
secreted IL8 levels after 24 h incubation with PLX4032 in BRAF
WT (YUDOSO, YUFIC and YUKIM), but not in mutant melanoma cells (YULAC).
Error bars represent STDV of six wells.
Halaban et al.
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RSK downstream target (21) was also acti-
vated (Figure 4B).
Real time RT-PCR demonstrated that known early
response genes, FOS and JUNB, were activated within
30 min in YUDOSO-BRAF
WT melanoma cells in
response to PLX4032, an effect that was persistent for
up to 8 h, whereas FOS was downregulated within
30 min in YULAC-BRAF
V600E cells (Figure 4C), in agree-
ment with the kinetics of ERK1⁄2 functional activation
and inactivation in wild-type and mutant cells, respec-
tively.
We explored the spectrum of affected genes by
hybridization to NimbleGen whole genome gene expres-
sion arrays, comparing untreated to PLX4032 treated (8
and 24 h) YUDOSO-BRAF
WT melanoma cells. The
results showed strong upregulation (3-fold and more) of
28 genes in response to PLX4032, including the early
response genes EGR1 and EGR3 (Figure 4D). Of inter-
est is the persistent activation of IL8 and LIF by 6.3-
and 12.6-fold, respectively (Figure 4D, marked with red
circles), because these two are secreted proteins that
may serve as markers for ERK activation. Indeed, ELISA
tests conﬁrmed that PLX4032 activated IL8, showing
that the protein was secreted into the medium not only
in YUDOSO, but also in two additional BRAF
WT mela-
noma cells YUKIM and YUFIC, while it was not acti-
vated in YULAC BRAF
V600E cells (Figure 4E).
Gene set enrichment analysis (GSEA) demonstrated
upregulation of downstream targets of EGR1, ATF2 and
CREB with a FDR (false discovery rate) of less then
25%, consistent with CREB activation (Figure 4B).
GSEA pathway analysis featured a ‘Ras Oncogenic
Signature’ (Bild et al., 2006) and TGFB as the top gene
sets with a FDR of less then 5%. The full list of
PLX4032 induced changed genes are provided in
Table S2 and will be uploaded on the GEO proﬁle site.
Functional responses to PLX4032
One of the main questions raised by our studies is
whether ERK activation had any impact on cellular func-
tions, because we did not detect a signiﬁcant increase
in the proliferation rate of advanced BRAF
WT melanoma
cells treated with PLX4032. We reasoned that these
cells could not be further stimulated because they were
proliferating already at their maximal rate, but cells from
early stage melanoma that did not gain full indepen-
dence from external growth factors required by normal
melanocytes (Bo ¨hm et al., 1995), may respond differ-
ently. To explore this notion, we examined the effect of
PLX4032 on primary melanoma cells, YULOVY isolated
from a 1.38 mm primary cutaneous lesion and YUFULO
ocular melanoma, both harboring the NRAS Q61L muta-
tion, compared with melanocytes from a giant nevus
(YUREEL-NV) and keratinocytes, all wild-type for BRAF
and NRAS.
In agreement with this concept, YULOVY and YUFU-
LO cells that require bFGF, IBMX and TPA for optimal
proliferation (Figure 5A), were stimulated by PLX4032
when incubated in suboptimal conditions, i.e. with bFGF
and IBMX (Figure 5B, solid dark lines), but not in the full
spectrum of required growth factors (Figure 5B, broken
dark line). In contrast, the keratinocytes were inhibited in
the presence or absence of growth supplements, with a
similar IC50 of 1.54 and 1.6 lM, respectively (Figure 5B,
solid and broken gray lines). Interestingly, YUREEL-NV
melanocytes that are wild-type for BRAF and NRAS, and
also mitogen-dependent, were not affected under any
conditions (Figure 5C). It should be noted that during this
AB C
Figure 5. Proliferation of mitogen-dependent cells in response to PLX4032. (A) YULOVY and YUFULO cell proliferation after incubation for
72 h in basal medium (none) or medium supplemented with growth factors as indicated. Values are averages of triplicate wells expressed as
percent of control (Day 0). (B) Dose response to increasing concentrations of PLX4032. YULOVY and YUFULO, solid dark lines with X and
solid circles, respectively, grown in medium supplemented with bFGF and IBMX; YULOVY cells grown with bFGF and IBMX, broken dark line;
Keratinocytes grown without and with supplements, gray solid and broken lines, respectively. Other details as in Figure 1. (C) YUREEL-NV
melanocyte proliferation in basal medium without growth factors (none), and with growth factors (as indicated) in the absence and presence
of PLX4032. Error bars represent STDV of triplicate wells.
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whether or not supplements were provided.
PLX4032 also had physiological effects on advanced
melanoma cells. We observed enhanced detachment of
BRAF
WT melanoma cells after treatment with PLX4032
for several hours that were 99% viable (Figure 6A). In
contrast, the number of YULAC-BRAF
V600E ﬂoating cells
did not change under similar conditions (about 700 cells
in 60 mm Petri dish seeded at 90% conﬂuency). This led
us to assess focal adhesion kinase (FAK) activation and
changes in cell adhesion and migration (Mitra et al.,
2005). The results showed an increase in phospho-FAK
(S910), the ERK1⁄2 phosphorylation site, in YUDOSO-
BRAF
WT and a reduction in YULAC-BRAF
V600E mela-
noma cells (Figure 6B, pFAK S910). Although there was
a slight increase in phospho-FAK S910 within 1 h, the
major activation occurred 8 h later and was maintained
at high levels further on (Figure 6B, compare pFAK S910
with pERK1⁄2), suggesting an intermediary limiting step.
Two additional assays conﬁrmed that activated FAK
had a functional impact on BRAF
WT melanoma cells.
First, there was a dramatic reduction in colony formation
in soft agar in response to PLX4032 (Figure 6C),
although the number of viable cells was similar (Fig-
ure 6C, MTS). Second, the transwell-based migration
assay showed that PLX4032 enhanced the motility of
YUDOSO-BRAF
WT, but not that of YULAC-BRAF
V600E
melanoma cells (Figure 6D(a, b)). There was approxi-
mately fourfold increase in YUDOSO-BRAF
WT migrating
cells compared with control, whereas the number of
migrating YULAC-BRAF
V600E melanoma cells was
reduced by 30% (Figure 6D(b)). In contrast, PLX4032
did not affect cell invasion, because very few YUDOSO-
BRAF
WT cells invaded through the Matrigel after 24, 48,
and 72-h incubation in the absence or presence of
PLX4032 (data not shown).
Discussion
In the studies described here, we employed cultured
melanoma cells freshly isolated from individual patients’
tumors as well as normal skin cells to investigate the
impact of genetic variations on current therapy with
PLX4032. We demonstrated that while PLX4032 inhib-
ited ERK1⁄2 in BRAF
V600E ⁄ K, it activated this signaling
pathway in BRAF
WT melanoma cells via stimulation of
RAF1 in a RAS-independent manner. Activating muta-
tions in NRAS and b-catenin, or loss of PTEN did not
affect the responses of BRAF
WT melanoma cells to this
BRAF inhibitor. PLX4032 enhanced the rate of prolifera-
tion of mitogen-dependent primary melanoma cells car-
rying the NRAS Q61L mutation, and decreased
adhesion and increased migration, of rapidly dividing
melanoma cells from advanced lesions, changes that
may confer tumor advantage in vivo. Interestingly, while
the proliferation of benign melanocytes isolated from a
giant nevus was not affected, the drug inhibited kerati-
nocytes. The latter results are not in contradiction with
in vivo observations, i.e. an increase in the incidence of
cutaneous squamous cell carcinoma in patients chroni-
cally exposed to the drug (Flaherty et al., 2009),
because the keratinocytes were isolated from basal and
not squamous epithelium, which is composed of differ-
entiated cells likely to have different growth properties.
We also report for the ﬁrst time inhibition of the
ERK1⁄2 kinase MEKK3 in BRAF
WT cells treated with
this PLX4032.
A
C
D
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Figure 6. PLX4032 reduced cell adhesion and promoted migration
in BRAF
WT melanoma cells. (A) The histograms show the number
of ﬂoating YUDOSO-BRAF
WT melanoma cells at different time
intervals (in hours) after the addition of PLX4032 as percent of
control (2500 ﬂoating cells). (B) Changes in FAK activation in
response to PLX4032, as detected by Western blotting with
antibodies against phospho FAK (S910), FAK, phospho-ERK1⁄2,
ERK1⁄2 and actin. (C) Low magniﬁcation photomicrographs of
10 days soft agar cultures showing YUDOSO-BRAF
WT cells forming
large colonies in control (DMSO), but single cells or small colonies
in PLX4032. The histogram demonstrates the viability (MTS) of
cells in 96-well soft agar plates measuring absorbance at 490 nm.
(D) Cell migration in response to PLX4032. The histograms show
the number of cells that migrated thorough the transwell pores by
counting three microscopical ﬁelds after 8 h treatment (a), or by
extracting the stained cells and measuring absorbance at 570 nm
after 24 h incubation with the drug normalized to control, DMSO
treated cells (b).
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SB-590885 and ZM 336372, has been reported before
(Hall-Jackson et al., 1999; King et al., 2006), but the
mechanism and consequences of such activation were
not explored in these previous studies. In the course of
peer review, two manuscripts were published that con-
ﬁrm our results (Hatzivassiliou et al., 2010; Heidorn
et al., 2010). In these reports, the investigators also
observed that selective BRAF inhibitors, such as
PLX4720, 885-A and GDC-0879 stimulated MEK–ERK
signaling in BRAF wild-type melanoma and carcinoma
cells via RAF1 activation (Hatzivassiliou et al., 2010;
Heidorn et al., 2010). Dr Marais and his collaborators
went one step further, showing that mutationally inac-
tive BRAF
D594A cooperates with oncogenic KRAS
K12D
in inducing melanoma in genetically engineered mice in
vivo. The results of both groups support a model in
which the BRAF-speciﬁc inhibitors induce RAS-GTP-
dependent RAF1 activation via the formation of BRAF-
RAF heterodimers or RAF1 homodimers followed by
recruitment of RAF1 to the plasma membrane, trigger-
ing the MEK-ERK pathway (Hatzivassiliou et al., 2010;
Heidorn et al., 2010). In support of this mechanism, the
investigators demonstrated co-immunoprecipitation of
RAF1 with BRAF
WT after treatment with 885-A (Heidorn
et al., 2010), or GDC-0879 (Hatzivassiliou et al., 2010),
RAF1 kinase-domain homodimers when co-crystallized
with GDC-0879 (Hatzivassiliou et al., 2010), and
the translocation of BRAF and RAF1 to the plasma
membrane accompanied by increased RAF1(S338) phos-
phorylation (Hatzivassiliou et al., 2010). In addition, the
BRAF-inhibitors induced about 30% increase in the pro-
liferation of established carcinoma cells (but not mela-
noma cell lines) derived from different tumors
(Hatzivassiliou et al., 2010). However, as in our studies,
both groups failed to detect BRAF-RAF1 heterodimers
in response to PLX4720, a drug structurally related to
PLX4032, and PLX4720 did not induce BRAF and RAF1
translocation to the membrane or an increase in
RAF1(S338) phosphorylation (Hatzivassiliou et al., 2010).
Furthermore, crystal structure revealed distinct differ-
ences in the mode of PLX4720 and GDC-0879 interac-
tion with BRAF. While PLX4720 binding disrupts ion
pairing, shifting the aC helix which inactivates the
kinase, binding of GDC-0879 maintains the ion pair,
orienting the aC-helix into an active conformation
(Hatzivassiliou et al., 2010).
Altogether, although we have not uncovered the
mechanism by which PLX4032 activated RAF1 in
BRAF
WT melanoma cells, our data are consistent with
the published reports and suggest that PLX4032 may
have a different mode of action, which is independent
of RAS-GTP because mutant RAF1 R89L that does not
bind RAS was also activated to the same degree as its
Table 1. Sources of patient’s derived melanoma cells and their mutations status
Melanoma Gender⁄age Stage⁄site BRAF⁄NRAS mutation PTEN
Wild-type for BRAF and NRAS
YUHEF M⁄52 IV, lung WT WT
YUVON M⁄63 IV, acral WT WT
YUROB F⁄76 II, abdominal wall WT LOH
YUSIV F⁄61 IV, chest WT WT
YUKIM F⁄71 III, lymph node WT WT, LOH
BRAF mutants⁄NRAS wild-type
YUMAC M⁄68 IV, soft tissue, thigh V600K WT
YUGEN8 F⁄44 IV, brain V600E Null
YUHUY M⁄64 II, lymph node V600E Null
YUSAC2 M⁄57 IV, soft tissue, neck V600E WT⁄LOH
YULAC F⁄66 IV, soft tissue, neck V600K P38S⁄LOH (C1143T)
YURIF M⁄52 IV, soft tissue, thigh V600K WT
WW165 F⁄62 Primary melanoma, 2.25 mm V600K⁄WT WT
YUKOLI M⁄53 IV, lymph node V600E⁄WT WT
YUSIT1 M⁄67 IV, unknown V600K⁄WT WT
YUSIK F⁄49 IV, lymph node V600E⁄WT WT
501 mel
a Not known IV, lymph node V600E⁄WT WT
YUMUT M⁄44 III, soft tissue, wrist V600E⁄WT Null
NRAS mutants⁄BRAF wild-type
YULOVY F⁄83 I, primary melanoma, right medial calf, 1.38 mm Q61L⁄WT WT
YUDOSO M⁄84 llb, primary melanoma, left abdomen, 2.5 mm Q61K⁄WT WT
YUDEDE M⁄83 III, soft tissue, pretibial Q61H Null
YUFIC M⁄65 IV, lymph node Q61R⁄WT WT
YUFULO M⁄87 Primary, choroid Q61L⁄WT ND
ND, not determined.
aThe melanoma cell 501 mel carries also activating S33C mutations in mutation in b-catenin (Halaban et al., 2009).
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like PLX4720, induces weak hetero- or homo- RAF
dimers, as suggested by Marais and his collaborators
that is not sustained through experimental manipula-
tions.
In our hands, the presence of mutant NRAS in
BRAF
WT melanoma cells was not required for PLX4032
induced ERK activation, cell detachment, loss of adher-
ence and migration. However, so far, drug induced pro-
motion of cell proliferation was observed in two NRAS
mutant primary melanoma cell strains that did not
acquire full independence from environmental growth
stimuli. Therefore, dependency of growth response on
NRAS mutation after treatment with PLX4032 should be
further explored once growth factor-dependent
BRAF
WT⁄NRAS
WT melanoma cells become available.
Altogether, our studies demonstrate persistence ERK
activation in response to BRAF inhibition in BRAF
wt mel-
anoma cells, the consequences on several downstream
targets, the upregulation of a wide scope of ERK-
responsive genes and the physiological changes that
can confer growth advantage to these cells.
An important factor in cancer management is the
ability to choose patients for speciﬁc therapy, monitor
treatment and assess response. Very frequently, the
presence of the activated target is not sufﬁcient
to assume responsiveness as shown for the acti-
vated⁄ampliﬁed EGFR where the levels of phosphory-
lated downstream mediators, Akt, ERK1⁄2 and Stat3
served as better markers (Emery et al., 2009). We dem-
onstrated that melanoma cells heterozygous for V600E,
but not V600K BRAF alleles were less sensitive to the
inhibitory effect of PLX4032 and maybe be considered
in patient selection and treatment. Our studies also sug-
gest that monitoring the status of phospho-ERK1⁄2 and
phospho-FAK S910 in tumor biopsies can be a good
indicator for adverse effects, and that blood levels of
IL8 and LIF may serve as markers, because normal cells
were either inhibited or not-responsive to the drug.
Materials and methods
Cells
The melanoma cells listed in Table 1 were isolated from primary
and metastatic lesions and the normal melanocytes from a giant
nevus, all excised to improve patient quality of life. The specimens
were collected with participants’ informed consent according to
Health Insurance Portability and Accountability Act (HIPAA) regula-
tions with Human Investigative Committee protocol. The melanoma
cells from advanced lesions were grown in OptiMEM (Invitrogen,
Carlsbad, CA, USA) supplemented with antibiotics and 5% fetal calf
serum (basal medium). WW165 cells were cultured in basal med-
ium supplemented with 3-isobutyl-1-methylxanthine (IBMX; Sigma-
Aldrich, St Louis, MO, USA), and YULOVY, YUFULO and YUREEL-
NV with recombinant ﬁbroblast growth factor 2 (bFGF; Promega,
Madison, WI, USA), IBMX and 12-O-tetradecanoylphorbol-13-ace-
tate (TPA; Sigma), ingredients required for optimal proliferation
(Bo ¨hm et al., 1995; Hoek et al., 2004). YUSIT1, 501 mel, YUGEN8
and WW165 were long-term cultures and the rest were early,
short-term passage (passage 2–15). Keratinocytes were cultured
from newborn foreskins in EpiLife medium (Cascade Biologics,
Portland, OR, USA) and used during the ﬁrst passage. BRAF, NRAS
and PTEN mutations were identiﬁed by Sanger sequencing of
gene-speciﬁc amplicons (Tables S1).
Proliferation, migration and invasion assays
Cell proliferation was measured after 72-h incubation with increas-
ing concentrations of PLX4032 (kindly provided by Plexxikon, Inc.,
Berkeley, CA, USA) employing the CellTiter-Glo
  Luminescent Cell
Viability Assay (Promega Corporation). The IC50 values (the dose
that elicits 50% inhibition compared to vehicle control) were calcu-
lated from the slope of the drug response by linear interpolation.
Soft agar colony formation was assessed after 10 days incubation
with PLX4032 (1 lM) or DMSO (0.1%) by microscopical visualiza-
tion. Soft agar cell viability was determined in 96 well plates with
the CellTiter 96
  AQueous One Solution Cell Proliferation Assay
(MTS; Promega). Cell migration and invasion were evaluated with
the CytoSelect
TM 24-well kit (8 lm pore size, CBA-100-C; Cell Biol-
abs, Inc, San Diego, CA, USA). Migration was determined after 8
and 24 h incubations with PLX4032 (1 lM) or DMSO (0.1%). The
number of cells that had migrated to the lower surface of the
membrane was counted in three random ﬁelds or after colorimetric
measurement at 570 nm.
Western blotting and intracellular signaling
Melanoma cells were incubated with DMSO (0.1%) or PLX4032 (as
indicated). Cell pellets were lysed in RIPA buffer supplemented with
protease and phosphatase inhibitors, sonicated and centrifuged.
Total cell extracts (16 lg protein⁄lane) estimated with the BioRad kit
(Bio-Rad Laboratories, Hercules, CA, USA), were subjected to
Western blot analyses (Halaban et al., 2009). The antibodies used
were phospho-Mek1⁄2 pSer217⁄221, MEK1⁄2, phospho-Erk2
pThr202⁄Tyr204 (mAb), ERK1⁄2 (ERK 1⁄2, 137F5), phospho-p90RSK
Ser380 (9D9 Rabbit mAb), phospho-p90RSK Thr359⁄Ser363, phos-
pho-p90RSK Thr573, RSK1⁄RSK2⁄RSK3 (32D7), FAK (all from Cell
Signaling Technology, Beverly, MA, USA), anti-actin (Sigma; mouse
mAb), pFAK (S910; BioSource
 , Invitrogen Corporation, Carlsbad,
CA, USA, Cat # 44-596G), BRAF (goat AF3424; R&D Systems, Min-
neapolis, MN, USA), CREB-1 (24H4B; Santa Cruz Biotechnologies,
Inc, Santa Cruz, CA, USA) and phospho-Ser133 CREB-1 rabbit poly-
clonal antibodies (20), and others described in Appendix S1. X-ray
ﬁlms were scanned and density of bands was assessed with ImageJ
1.42q (National Institutes of Health).
Immune complex kinase assay
Melanoma cells were treated with PLX4032 (1 lM) or DMSO for
the indicated period of time, collected by scraping on ice, washed
with cold PBS containing phenylarsine oxide, lysed in NP40 (1%) or
CHAPS (0.1%) lysis buffer supplemented with protease and phos-
phatase inhibitors, and PLX4032 (200 nM) for drug-treated cells.
Antibodies against BRAF (H-145; Santa Cruz Biotechnology, Inc),
RAF1 (#9422; Cell Signaling Technology), MEKK3 (C-term, EP600Y;
Epitomics, Burlingame, CA, USA), and rabbit IgG (as a negative
control) were pre-bound to Dynabeads Protein G (Invitrogen). After
three washes with lysis buffer, the beads were incubated with the
cell lysates (200 lg proteins⁄assay, 100 ll ﬁnal volume) for 30 min
on a rotating wheel, and kinase activity was assessed on the bead-
bound immune-complexes employing the Raf-1 Kinase Cascade
Assay Kit (UPSTATE Cell Signaling Solutions, Millipore, Temecula,
CA, USA) which measures the levels of [c
32P]-ATP incorporated
into MBP. Kinase activities are expressed as pmol ATP incorpo-
rated into MBP⁄min after subtraction of control IgG values. Precipi-
tated proteins were subsequently eluted with SDS sample buffer
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(goat), RAF1 (mouse mAb, E-10, sc-7267; Santa Cruz Biotechnol-
ogy, Inc), or MEKK3 (mouse mAb, Clone 40; BD Biosciences, San
Jose, CA, USA).
RAF1 suppression by siRNA
YUFIC melanoma cells were transfected with RAF1 siRNA (Smart
pool siRNA; Dharmacon Inc; Chicago, IL, USA, Cat # L-087699-00),
or Alexa Fluor 488 siRNA (100 nM⁄each) employing the Dharma-
FECT transfection reagent. At the end of 48 h, the cells were trea-
ted with PLX4032 or DMSO for 2 h, harvested and processed for
Western blot analysis as above.
Transfections
For kinase assays, YUFIC-BRAF
WT Melanoma cells were transiently
transfected with plasmids encoding FLAG-tagged RAF1 or RAF1
R89L mutant that does not bind Ras (Dent et al., 1995; Laird et al.,
1999) (kindly provided by Dr Deborah K. Morrison), using the Lipo-
fectamine
TM 2000 reagent (Invitrogen). Cells were treated with
PLX4032 (1 lM) or DMSO for 16 h, after 32 h transfection, lysed
in 0.1% CHAPS buffer, and anti-FLAG antibodies (M2; Sigma) and
immune-complexes were tested for kinase activity as described
above. The levels of immunoprecipitated proteins were assessed
by Western blotting with anti-c-RAF (CST) antibodies. For RAF
dimerization, melanoma cells (YUFIC-BRAF
WT and YULAC-
BRAF
V600E)) were co-transfected with FLAG-tagged RAF1 and
Myc-His tagged RAF1 plasmids, harvested 2 days later after 12 h
treatment with PLX4032 or DMSO, and cell lysates (200 lg⁄each)
were subjected to immunoprecipitation with anti-Myc antibodies
(c-Myc, sc-789; Santa Cruz Biotechnology, Inc) and Western
blotting with anti-FLAG (M2 mAb) or anti-BRAF (goat) antibodies.
Gene expression in response to PLX4032
YUDOSO-BRAF
WT cells were treated with PLX4032 (1 lM) for 8
and 24 h, or DMSO (24 h), RNA was extracted, processed for
hybridization to NimbleGen arrays (A4542-00-01, design name
HG18 60mer at Yale W. M. Keck microarray core facility and the
results were subjected to bioinformatic analysis (Halaban et al.,
2009). Changes in mRNA levels were validated by quantitative real-
time RT-PCR employing ABI 7500 Real-Time PCR Systems (Applied
Biosystems). ACTB expression was used as a reference to normal-
ize for input cDNA. Gene speciﬁc primers are listed in Table S1.
ELISA
IL8 levels secreted to the culture medium were measured after 24-
h treatment with PLX4032 (1 lM) or DMSO with R&D DuoSet
ELISA (#DY208).
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